Seroprotection rate (titre ≥1/40) | ||||
---|---|---|---|---|
Before immunisation | After immunisation | |||
N | % (95% CI) | Seroconversion rate | ||
ARD | 1668 | 10.3 (8.8 to 11.8) | 68.5 (66.3 to 70.7)* | 63.4 (61.1 to 65.7)* |
SLE | 572 | 8.9 (6.6 to 11.2) | 64.9 (61.0 to 68.8)* | 60.5 (56.5 to 64.5)* |
RA | 343 | 10.8 (7.5 to 14.1) | 60.1 (54.9 to 65.3)* | 53.4 (48.1 to 58.7)* |
PsA | 101 | 7.9 (2.6 to 13.2) | 65.3 (56.0 to 74.6)* | 57.4 (47.8 to 67.0)* |
AS | 152 | 8.6 (4.1 to 13.1) | 73.7 (66.7 to 80.7)* | 69.8 (62.5 to 77.1) |
BD | 85 | 7.1 (1.6 to 12.6) | 71.8 (62.2 to 81.4)* | 69.4 (59.6 to 79.2) |
DM | 45 | 8.9 (0.6 to 17.2) | 68.9 (55.4 to 82.4)* | 66.7 (52.9 to 80.5) |
SSc | 127 | 18.1 (11.4 to 24.8) | 81.1 (74.3 to 87.9) | 73.2 (65.5 to 80.9) |
MCTD | 69 | 10.1 (3.0 to 17.2) | 75.4 (65.2 to 85.6) | 68.1 (57.1 to 79.1) |
PAPS | 54 | 5.6 (−0.5 to 11.7) | 79.6 (68.8 to 90.3) | 77.8 (66.7 to 88.9) |
pSS | 36 | 11.1 (0.8 to 21.4) | 83.3 (71.1 to 95.5) | 77.8 (64.2 to 91.4) |
TA | 30 | 13.3 (1.1 to 25.4) | 90 (79.3 to 100.7) | 86.7 (74.5 to 98.8) |
PM | 28 | 21.4 (6.2 to 36.6) | 82.1 (67.9 to 96.3) | 82.1 (67.8 to 96.3) |
WG | 26 | 19.2 (4.1 to 34.3) | 69.2 (51.4 to 86.9) | 65.4 (47.1 to 83.7) |
Control | 234 | 11.5 (7.4 to 15.6) | 82.9 (78.1 to 87.7) | 76.9 (71.5 to 82.3) |
Data are expressed in % (95% CI).
↵* p<0.05. Comparison between patients and controls
ARD, autoimmune rheumatic diseases; AS, ankylosing spondylitis; BD, Behçet's disease; DM, dermatomyositis; MCTD, mixed connective tissue disease; PAPS, primary antiphospholipid syndrome; PM, polymyositis; PsA, psoriatic arthritis; pSS, primary Sjögren's syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; TA, Takayasu's arteritis; WG, Wegener's granulomatosis.